Annals of Surgical Oncology

, Volume 25, Issue 3, pp 655–659 | Cite as

Implications of Hyperthermic Intraperitoneal Chemotherapy Perfusion-Related Hyperglycemia

  • Camille L. StewartEmail author
  • Ana Gleisner
  • Alison Halpern
  • Irada Ibrahim-Zada
  • Rodrigo Asturias Luna
  • Nathan Pearlman
  • Csaba Gajdos
  • Barish Edil
  • Martin McCarter
Colorectal Cancer



Hyperthermic intraperitoneal chemotherapy (HIPEC) administration can be associated with hyperglycemia during perfusion. Little is known about this effect, and no previous studies have examined patient characteristics associated with perfusion-related hyperglycemia.


We retrospectively identified consecutive patients at a single institution treated with HIPEC from 8/2003 to 10/2016 who had intraoperative blood glucose measured. Hypertonic 1.5% dextrose-containing peritoneal dialysate was used as carrier solution in all patients. Comparisons were made using parametric [Student’s t test, analysis of variance (ANOVA)], and nonparametric tests (χ 2, Kruskal–Wallis) where appropriate.


There were 85 patients identified, with average age of 53 ± 12 years, 69 (81%) with appendiceal or colorectal peritoneal cancer. Most patients were perfused with mitomycin C (69%) or oxaliplatin (24%). Intraoperative hyperglycemia (> 180 mg/dL) affected the majority of patients (86%), with values up to 651 mg/dL. Insulin was required for treatment in 66% of patients. Peak hyperglycemia occurred within an hour of perfusion in 91%, and resolved by postoperative day one in 91% of patients. Glucose > 309 mg/dL (highest quartile) was associated with longer operating time (p = 0.03) and with use of oxaliplatin compared with mitomycin C (p = 0.01). No association was found with other comorbidities, peritoneal carcinomatosis index score, or postoperative outcomes.


Most patients experience hyperglycemia during HIPEC. This is not clearly associated with patient factors, and may be due to use of dextrose-containing carrier solution. Since perioperative hyperglycemia has potential negative impact, use of dextrose-containing carrier solution should be questioned and is worth investigating further.





  1. 1.
    Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005; 130:1144.e1–1144.e8.CrossRefGoogle Scholar
  2. 2.
    Gandhi GY, Nuttall GA, Abel MD, et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc. 2005; 80:862–866.CrossRefPubMedGoogle Scholar
  3. 3.
    Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg. 2013; 257:8–14.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Park C, Hsu C, Neelakanta G, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009; 87:1031–1036.CrossRefPubMedGoogle Scholar
  5. 5.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21:3737–3743.CrossRefPubMedGoogle Scholar
  6. 6.
    Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008; 15:2426–2432.CrossRefPubMedGoogle Scholar
  7. 7.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28:63–68.CrossRefPubMedGoogle Scholar
  8. 8.
    Elias D, Honoré C, Ciuchendéa R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008; 95:1164–1171.CrossRefPubMedGoogle Scholar
  9. 9.
    Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev. 2016; 48:42–49.CrossRefPubMedGoogle Scholar
  10. 10.
    Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014; 21:1501–1505.CrossRefPubMedGoogle Scholar
  11. 11.
    González-Moreno S1, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010; 2:68–75CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008; 98:247–252.CrossRefPubMedGoogle Scholar
  13. 13.
    Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006; 57:703–708.CrossRefPubMedGoogle Scholar
  14. 14.
    Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of surgical oncology. Ann Surg Oncol. 2007; 14:128–133.CrossRefPubMedGoogle Scholar
  15. 15.
    De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, Mortier E. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008; 28:61–66.PubMedGoogle Scholar
  16. 16.
    Rueth NM, Murray SE, Huddleston SJ, Abbott AM, Greeno EW, Kirstein MN, Tuttle TM. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011; 18:174–180.CrossRefPubMedGoogle Scholar
  17. 17.
    Mehta AM, Van den Hoven JM, Rosing H, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015; 479:23–27.CrossRefPubMedGoogle Scholar
  18. 18.
    Twardowski ZJ, Nolph KD, Rhanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP. Peritoneal equilibrium test. Perit Dial Bull. 1987; 7:138–147.Google Scholar
  19. 19.
    van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345:1359–1367.CrossRefPubMedGoogle Scholar
  20. 20.
    Russo N. Perioperative glycemic control. Anesthesiol Clin. 2012; 30:445–466.CrossRefPubMedGoogle Scholar
  21. 21.
    Kwon S, Thompson R, Dellinger P, Yanez D. Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg. 2013; 257:8–14.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001; 24:371–381.CrossRefPubMedGoogle Scholar
  23. 23.
    Lazar HL, McDonnell M, Chipkin SR, et al. The society of thoracic surgeons practice guideline series: blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009; 87:663–669.CrossRefPubMedGoogle Scholar
  24. 24.
    Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin North Am. 2003; 12:813–824.CrossRefGoogle Scholar
  25. 25.
    Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001; 47:269–276.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Camille L. Stewart
    • 1
    Email author
  • Ana Gleisner
    • 1
  • Alison Halpern
    • 1
  • Irada Ibrahim-Zada
    • 1
  • Rodrigo Asturias Luna
    • 1
  • Nathan Pearlman
    • 1
  • Csaba Gajdos
    • 1
  • Barish Edil
    • 1
  • Martin McCarter
    • 1
  1. 1.Department of SurgeryThe University of Colorado School of MedicineAuroraUSA

Personalised recommendations